TY - JOUR
T1 - Hybrid Compounds Containing Carvacrol Scaffold
T2 - In Vitro Antibacterial and Cytotoxicity Evaluation
AU - Mbese, Zintle
AU - Nell, Margo
AU - Fonkui, Youmbi T.
AU - Ndinteh, Derek T.
AU - Steenkamp, Vanessa
AU - Aderibigbe, Blessing A.
N1 - Publisher Copyright:
© 2022 Bentham Science Publishers.
PY - 2022/4
Y1 - 2022/4
N2 - Background: The design of hybrid compounds is a distinct approach for developing potent bioactive agents. Carvacrol, an essential oil, exhibits antimicrobial, antifungal, antioxidant, and anticancer activity, making it a good precursor for the development of compounds with potent biological activities. Some patents have reported carvacrol derivatives with promising biological activities. Objective: This study aimed to prepare hybrid compounds containing a carvacrol scaffold with significant antibacterial and anticancer activity. Methods: Esterification reactions between carvacrol and known pharmacophores were performed at room temperature and characterized using1 H-NMR,13 C-NMR, and UHPLC-HRMS. In vitro antibacterial study was determined using the microdilution assay and cytotoxicity evaluation using sulforhodamine B staining assay. Results: The FTIR spectra of the carvacrol hybrids revealed prominent bands in the range of 1612-1764 cm-1 and 1014-1280 cm-1 due to (C=O) and (C-O) stretching vibrations, respectively. The structures of the carvacrol hybrids were confirmed by1H-NMR,13C-NMR, and UHPLC-HRMS analysis, and compound 5 exhibited superior activity when compared to the hybrid compounds against the strains of bacteria used in the study. The in vitro cytotoxicity evaluation showed that compound 3 induced cytotoxicity in all the cancer cell lines; MDA (16.57 ± 1.14 μM), MCF-7 (0.47 ± 1.14 μM), and DU145 (16.25 ± 1.08 μM), as well as the normal breast cells, MCF-12A (0.75± 1.30 μM). Compound 7 did not induce cytotoxicity in the cell lines tested (IC50 > 200 μM). Conclusion: The modification of carvacrol through hybridization is a promising approach to develop compounds with significant antibacterial and anticancer activity.
AB - Background: The design of hybrid compounds is a distinct approach for developing potent bioactive agents. Carvacrol, an essential oil, exhibits antimicrobial, antifungal, antioxidant, and anticancer activity, making it a good precursor for the development of compounds with potent biological activities. Some patents have reported carvacrol derivatives with promising biological activities. Objective: This study aimed to prepare hybrid compounds containing a carvacrol scaffold with significant antibacterial and anticancer activity. Methods: Esterification reactions between carvacrol and known pharmacophores were performed at room temperature and characterized using1 H-NMR,13 C-NMR, and UHPLC-HRMS. In vitro antibacterial study was determined using the microdilution assay and cytotoxicity evaluation using sulforhodamine B staining assay. Results: The FTIR spectra of the carvacrol hybrids revealed prominent bands in the range of 1612-1764 cm-1 and 1014-1280 cm-1 due to (C=O) and (C-O) stretching vibrations, respectively. The structures of the carvacrol hybrids were confirmed by1H-NMR,13C-NMR, and UHPLC-HRMS analysis, and compound 5 exhibited superior activity when compared to the hybrid compounds against the strains of bacteria used in the study. The in vitro cytotoxicity evaluation showed that compound 3 induced cytotoxicity in all the cancer cell lines; MDA (16.57 ± 1.14 μM), MCF-7 (0.47 ± 1.14 μM), and DU145 (16.25 ± 1.08 μM), as well as the normal breast cells, MCF-12A (0.75± 1.30 μM). Compound 7 did not induce cytotoxicity in the cell lines tested (IC50 > 200 μM). Conclusion: The modification of carvacrol through hybridization is a promising approach to develop compounds with significant antibacterial and anticancer activity.
KW - antibacterial
KW - anticancer
KW - carvacrol
KW - Gram-negative bacteria
KW - Gram-positive bacteria
KW - hybrid compounds
UR - http://www.scopus.com/inward/record.url?scp=85139377748&partnerID=8YFLogxK
U2 - 10.2174/1574891X16666220124122445
DO - 10.2174/1574891X16666220124122445
M3 - Article
C2 - 35078393
AN - SCOPUS:85139377748
SN - 2772-4344
VL - 17
SP - 54
EP - 68
JO - Recent Advances in Anti-Infective Drug Discovery
JF - Recent Advances in Anti-Infective Drug Discovery
IS - 1
ER -